The highly-selective metabotropic glutamate receptor 2 positive allosteric modulator LY-487,379 alleviates psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmoset
Objective: To investigate the effect of metabotropic glutamate receptor 2 (mGluR2) activation on L-3,4-dihydroxyphenylalanine (L-DOPA)-induced psychosis-like behaviours (PLBs) and dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmoset…Capgras syndrome in advanced Parkinson disease
Objective: The aims of this study were to investigate the frequency of Capgras syndrome in Parkinson's disease patients who have undergone Deep Brain Stimulation (DBS)…Systematic Evaluation of Major and Minor Psychotic Symptoms in Parkinson’s Disease
Objective: To evaluate a structured clinical interview (SCI) based on the Parkinson’s disease-specific Scale for the Assessment of Positive Symptoms (SAPS-PD) in the identification of…Baseline Clinical Predictors of Future Psychotic Symptoms in de novo Parkinson Disease
Objective: To determine which baseline clinical symptoms are associated with future psychotic symptoms in de novo Parkinson disease (PD). Background: Because psychosis in PD is…Predictors of onset of psychosis in Parkinson’s disease: “Who gets it early?”
Objective: To explore the factors which may predict the onset of psychosis in Parkinson’s disease (PD). Background: Non-motor symptoms (NMS) are commonly observed in PD.…Treatment of Parkinson’s disease psychosis–a systematic review of RCTs
Objective: An SLR was conducted to assess the evidence from RCTs supporting the safety and efficacy of Parkinson’s disease psychosis (PDP) treatments. Background: PDP is…Domain-Specific Cognitive Impairment in Non-Demented Parkinson’s Disease Psychosis
Objective: Our objective was to determine whether psychosis in non-demented Parkinson’s disease (PD) patients is associated with domain-specific cognitive impairment on the Mini-Mental State Exam…Treatment of Psychosis in Parkinson’s Disease: Evidence-Based Recommendations Versus Actual Clinical Practice
Objective: To examine if actual clinical practice of antipsychotic use in Parkinson's Disease patients are consistent with published evidence-based reviews of treatment recommendations and discuss…Use of pimavanserin in patients with Parkinson’s disease psychosis: Subgroup analysis of efficacy and safety in patients with and without cognitive impairment
Objective: A planned subgroup analysis of a phase 3 study was performed to evaluate the efficacy and safety of pimavanserin (PIM) in Parkinson’s disease psychosis…A Phase 2 Study of Nelotanserin, a Novel 5HT2A Receptor Inverse Agonist, in Dementia with Lewy Bodies and Parkinson’s Disease Dementia Subjects Experiencing Visual Hallucinations
Objective: To evaluate the safety and efficacy of nelotanserin in Lewy body dementia subjects experiencing visual hallucinations. Background: Nelotanserin is a selective 5HT2A receptor inverse…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.